The Current Ratio as of December 2024 (TTM) for Virax Biolabs Group Limited (VRAX) is 25.94

According to Virax Biolabs Group Limited’s latest financial reports and current stock price. The company's current Current Ratio is 25.94. This represents a change of 112.76% compared to the average of 12.19 of the last 4 quarters.

Virax Biolabs Group Limited (VRAX) Historical Current Ratio (quarterly & annually)

How has VRAX Current Ratio performed in the past?

The mean historical Current Ratio of Virax Biolabs Group Limited over the last ten years is 7.33. The current 25.94 Current Ratio has changed 35.29% with respect to the historical average. Over the past ten years (40 quarters), VRAX's Current Ratio was at its highest in in the March 2024 quarter at 25.94. The Current Ratio was at its lowest in in the September 2020 quarter at 0.

Virax Biolabs Group Limited (VRAX) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Virax Biolabs Group Limited Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Virax Biolabs Group Limited (VRAX) Average Current Ratio

How has VRAX Current Ratio performed in the past?

The current Current Ratio of Virax Biolabs Group Limited (VRAX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Virax Biolabs Group Limited (VRAX) Current Ratio vs. Peers

How is VRAX’s Current Ratio compared to its peers?

Virax Biolabs Group Limited’s Current Ratio is greater than Blue Water Vaccines, Inc. (0.06), greater than Revelation Biosciences, Inc. (1.64), greater than Hillstream BioPharma, Inc. (2.25), greater than Kiora Pharmaceuticals, Inc. (8.97), greater than Quoin Pharmaceuticals, Ltd. (3.02), greater than NeuroBo Pharmaceuticals, Inc. (2.41), greater than Cardio Diagnostics Holdings, Inc. (8.51), greater than Allarity Therapeutics, Inc. (2.75), greater than Kiromic BioPharma, Inc. (0.22), greater than Biodexa Pharmaceuticals Plc (2.16), greater than Unicycive Therapeutics, Inc. (3.61), greater than PaxMedica, Inc. Common Stock (0.38),

Build a custom stock screener for Virax Biolabs Group Limited (VRAX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Virax Biolabs Group Limited using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Virax Biolabs Group Limited (VRAX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Virax Biolabs Group Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.